Jodi Michaels, MD
Urology · Woodbury, MNNPI 1922233287
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,295 of the $65,687 with a category attached, or 73.5%. Medtronic accounts for 96.5% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $26,167 and has fallen 61.4% since, to $10,102 in 2025. Among urology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $252.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$63K
- AbbVie$652
- Coloplast$300
- Boston Scientific$248
- Olympus America Inc.$170
- Convatec Inc.$137
- plus $800 from 20 others
Across 55 payments — averaging $2515.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$137K
- Ipsen Innovation$2K
What the payments were for
- Consulting fees$4,0866%
- Speaking & faculty fees$48,29574%
- Travel & lodging$6,24910%
- Food & beverage$7,05011%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 182 | $63,381 |
| AbbVie(2 entities) | 17 | $652 |
| Coloplast | 13 | $300 |
| Boston Scientific | 5 | $248 |
| Olympus America Inc. | 2 | $170 |
| Convatec Inc. | 7 | $137 |
| 180 Medical, Inc. | 6 | $134 |
| Axonics, Inc. | 5 | $97 |
| Caldera Medical, Inc | 1 | $83 |
| ABC Home Medical Supply, Inc. | 3 | $61 |
| Accord Healthcare, Inc. | 2 | $46 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $42 |
| SRS Medical Systems, Inc. | 1 | $40 |
| Progenics Pharmaceuticals, Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $39 |
| Procept Biorobotics Corporation | 1 | $33 |
| Pelvital USA, Inc. | 1 | $26 |
| Antares Pharma, Inc. | 1 | $22 |
| Coopersurgical, Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| Pfizer | 1 | $18 |
| Bayer | 1 | $18 |
| Hollister Incorporated | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Blue Earth Diagnostics | 1 | $16 |
| Urovant Sciences Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$56,976
- NURO$888
- BOTOX$450
- iTIND System$141
How this compares
$65,687 in reported general payments places this provider in the 95th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 492 | $503,450 |
| MyrbetriqMirabegron | 342 | $324,433 |
| Trospium Chloride ErTrospium Chloride | 133 | $37,292 |
| Estradiol | 409 | $35,734 |
| Methenamine Hippurate | 243 | $25,591 |
| Mirabegron ErMirabegron | 39 | $25,305 |
| Tolterodine Tartrate ErTolterodine Tartrate | 188 | $15,435 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 39 | $9,286 |
| Trospium Chloride | 143 | $8,467 |
| YuvafemEstradiol | 57 | $8,436 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 452 | $5,309 |
| Oxybutynin Chloride ErOxybutynin Chloride | 120 | $4,406 |
| Tamsulosin Hcl | 190 | $2,962 |
| Cephalexin | 289 | $2,758 |
| Potassium Citrate ErPotassium Citrate | 22 | $2,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $16 | $324,433342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 urology providers in Minnesota.
Other urology in Woodbury
- Steven SiegelWoodbury$140K
- Aaron MilbankWoodbury$97K
- Spencer HartWoodbury$69K
- Mikhail RegelmanWoodbury$10K
- Anthony PolcariWoodbury$7K
- Samuel KieleyWoodbury$6K
- David YangMankato$298K
- Steven BernsteinEdina$271K
- Ayman SoubraMinneapolis$204K
- Sean ElliottMinneapolis$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.